

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCLETIS PHARMA INC.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1672)

ANNOUNCEMENT

INSIDE INFORMATION

This announcement is made by Asclepis Pharma Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571).

The board of directors of the Company (the “**Board**”) is pleased to announce that Asclepis BioScience Co., Ltd. (歌禮生物科技(杭州)有限公司, “**Asclepis BioScience**”), a wholly-owned subsidiary of the Company, and Shanghai Roche Pharmaceuticals Ltd. (“**Roche Shanghai**”) entered into a partnership agreement on November 20, 2018 (the “**Partnership Agreement**”), pursuant to which, Roche Shanghai granted Asclepis BioScience an exclusive sales & marketing promotion right in Mainland China for Pegasys, a leading pegylated interferon treatment for Hepatitis B and C. Under the Partnership Agreement, Asclepis BioScience will utilize its marketing channels for sales and marketing promotion of Pegasys and is in turn entitled to receive a certain percentage of the sales revenue as consideration (the “**Cooperation**”). The Cooperation is expected to start from December 1, 2018.

The Company is of the view that, through the Partnership Agreement, a strategic partnership will be established by the parties, where both parties can combine their strengths and resources to create greater business value. Leveraging on the Group’s strong focus in the areas of viral Hepatitis, previous success in the partnership between both parties for Ganovo (Danoprevir) and strong Pegasys branding, the Group and Roche will be well-positioned to provide a complementary and comprehensive product portfolio to serve the high unmet medical needs for Chinese Hepatitis B and C patients.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People's Republic of China
November 20, 2018

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Mr. Wei FU, as non-executive Director; and Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.